이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Botanix Pharmaceuticals 관리

관리 기준 확인 3/4

Botanix Pharmaceuticals' CEO는 Howie McKibbon, Aug2023 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 A$ 1.06M, 51.1% 로 구성됩니다. 51.1% 급여 및 48.9% 보너스(회사 주식 및 옵션 포함). 는 A$ 1.34M 가치에 해당하는 회사 주식의 0.25% 직접 소유합니다. 1.34M. 경영진과 이사회의 평균 재임 기간은 각각 2.4 년과 4.9 년입니다.

주요 정보

Howie McKibbon

최고 경영자

AU$1.1m

총 보상

CEO 급여 비율	51.1%
CEO 임기	less than a year
CEO 소유권	0.3%
경영진 평균 재임 기간	2.4yrs
이사회 평균 재임 기간	4.9yrs

최근 관리 업데이트

Recent updates

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

Mar 21

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Sep 06

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Jan 03

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Sep 05

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

May 10

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Jan 24

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Nov 30

CEO 보상 분석

Howie McKibbon 의 보수는 Botanix Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Dec 31 2023	n/a	n/a	-AU$10m
Sep 30 2023	n/a	n/a	-AU$10m
Jun 30 2023	AU$1m	AU$542k	-AU$9m
Mar 31 2023	n/a	n/a	-AU$10m
Dec 31 2022	n/a	n/a	-AU$11m
Sep 30 2022	n/a	n/a	-AU$12m
Jun 30 2022	AU$585k	AU$126k	-AU$13m

보상 대 시장: Howie 의 총 보상 ($USD 708.48K )은 Australian 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 783.32K ).

보상과 수익: 회사가 수익성이 없는 동안 Howie 의 보상이 증가했습니다.

CEO

Howie McKibbon

less than a year

테뉴어

AU$1,062,005

보상

Dr. Howie McKibbon serves as Chief Executive Officer since August 24, 2023 and was its Chief Operating Officer since October 2022 until August 24, 2023. He served as Chief Commercial Officer at Botanix Pha...

리더십 팀

이름	위치	테뉴어	보상	소유권
Vincent Ippolito	MD & Executive Chairman	4.9yrs	AU$684.70k	0.69% A$ 3.6m
Howie McKibbon	Chief Executive Officer	less than a year	AU$1.06m	0.25% A$ 1.3m
Matthew Callahan	Executive Director	4.3yrs	AU$572.09k	4.74% A$ 25.0m
Jack Hoblitzell	Senior Vice President of Pharmaceutical Development	3.4yrs	데이터 없음	데이터 없음
Patricia Walker	Chief Medical Adviser	2.4yrs	데이터 없음	데이터 없음
Susan Park	Company Secretary	1.2yrs	데이터 없음	데이터 없음

2.4yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: BOT 의 관리팀은 경험 ( 2.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Vincent Ippolito	MD & Executive Chairman	4.9yrs	AU$684.70k	0.69% A$ 3.6m
Matthew Callahan	Executive Director	4.3yrs	AU$572.09k	4.74% A$ 25.0m
Stewart Washer	Independent Non-Executive Director	5.3yrs	AU$128.14k	0.14% A$ 727.0k
Henry Bosch	Non Executive Director	7.9yrs	AU$315.39k	1.2% A$ 6.3m
Daniel Sharp	Non-Executive Director	2.3yrs	AU$216.37k	0.14% A$ 714.0k

4.9yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: BOT 의 이사회는 경험(평균 재직 기간 4.9 년)으로 간주됩니다.

Botanix Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Recent updates

New major risk - Financial position

Will Botanix Pharmaceuticals (ASX:BOT) Spend Its Cash Wisely?

New minor risk - Financial position

Botanix Pharmaceuticals Limited, Annual General Meeting, Mar 01, 2024

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Botanix Pharmaceuticals Limited has filed a Follow-on Equity Offering in the amount of AUD 13.5 million.

Full year 2023 earnings released: AU$0.008 loss per share (vs AU$0.014 loss in FY 2022)

Here's Why We're Watching Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Executive Officer

Botanix Pharmaceuticals Limited, Annual General Meeting, Sep 18, 2023

New minor risk - Share price stability

Botanix Pharmaceuticals (ASX:BOT) Will Have To Spend Its Cash Wisely

Botanix Pharmaceuticals Limited Announces Confirmation Sofpironium Bromide Nda Formally Under Review

Less than half of directors are independent

Botanix Pharmaceuticals Limited Promotes Howie Mckibbon to Chief Operating Officer

Botanix Pharmaceuticals Limited Announces Positive Data from its BTX 1702 Phase 1B/2 Papulopustular Rosacea Clinical Study

Botanix Pharmaceuticals Limited Submits FDA New Drug Application for Sofpironium Bromide

Botanix Pharmaceuticals Limited, Annual General Meeting, Nov 03, 2022

Can Botanix Pharmaceuticals (ASX:BOT) Afford To Invest In Growth?

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.003 loss in FY 2021)

MD, President & Executive Chairman exercised options to buy AU$370k worth of stock.

Here's Why We're Not At All Concerned With Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Situation

Less than half of directors are independent

Botanix Pharmaceuticals Limited Appoints Howie Mckibbon as Chief Commercial Officer and Patricia Walker as Chief Medical Adviser

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

We're Not Very Worried About Botanix Pharmaceuticals' (ASX:BOT) Cash Burn Rate

Botanix Pharmaceuticals Limited Announces Launch of Canine Atopic Dermatitis Program

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.018 loss in FY 2020)

We Think Botanix Pharmaceuticals (ASX:BOT) Can Afford To Drive Business Growth

Botanix Pharmaceuticals Limited Announces Results from BTX 1204A Pilot Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

First half 2021 earnings released: EPS AU$0.001 (vs AU$0.008 loss in 1H 2020)

Botanix Pharmaceuticals Limited Expands Management Team

Botanix Pharmaceuticals Limited Announces Positive Top-Line Data from BTX 1801 Phase 2A Nasal Decolonisation Proof of Concept Study

The Botanix Pharmaceuticals (ASX:BOT) Share Price Has Gained 81% And Shareholders Are Hoping For More

Botanix Pharmaceuticals Limited Publishes Antimicrobial Data in Peer-Reviewed Research Journal

Botanix Pharmaceuticals Limited Provides Update on BTX 1801 Phase 2A Clinical Study

We're Hopeful That Botanix Pharmaceuticals (ASX:BOT) Will Use Its Cash Wisely

Botanix Pharmaceuticals Limited(ASX:BOT) dropped from S&P/ASX Emerging Companies Index

Full year earnings released - AU$0.018 loss per share

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령